Search

King Y. Poon

Supervisory Patent Examiner (ID: 13739, Phone: (571)272-7440 , Office: P/2675 )

Most Active Art Unit
2624
Art Unit(s)
2624, 2625, 2724, 2617, 2675
Total Applications
274
Issued Applications
174
Pending Applications
50
Abandoned Applications
53

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 19631209 [patent_doc_number] => 20240409658 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-12 [patent_title] => ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 18/657397 [patent_app_country] => US [patent_app_date] => 2024-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35380 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18657397 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/657397
ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES May 6, 2024 Abandoned
Array ( [id] => 19541651 [patent_doc_number] => 20240358687 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => USE OF NOX INHIBITORS FOR TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 18/651929 [patent_app_country] => US [patent_app_date] => 2024-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11526 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18651929 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/651929
USE OF NOX INHIBITORS FOR TREATMENT OF CANCER Apr 30, 2024 Pending
Array ( [id] => 19380997 [patent_doc_number] => 20240270867 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => HUMAN PD-L2 ANTIBODIES AND METHODS OF USE THEREFOR [patent_app_type] => utility [patent_app_number] => 18/611087 [patent_app_country] => US [patent_app_date] => 2024-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19580 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -57 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18611087 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/611087
Human PD-L2 antibodies and methods of use therefor Mar 19, 2024 Issued
Array ( [id] => 19331366 [patent_doc_number] => 20240245796 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 18/595275 [patent_app_country] => US [patent_app_date] => 2024-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 105152 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 211 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18595275 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/595275
LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME Mar 3, 2024 Abandoned
Array ( [id] => 19359393 [patent_doc_number] => 20240261427 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 18/595279 [patent_app_country] => US [patent_app_date] => 2024-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 105967 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18595279 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/595279
LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME Mar 3, 2024 Abandoned
Array ( [id] => 19448958 [patent_doc_number] => 20240309088 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/392623 [patent_app_country] => US [patent_app_date] => 2023-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 110752 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18392623 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/392623
ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE Dec 20, 2023 Abandoned
Array ( [id] => 19217856 [patent_doc_number] => 20240182560 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-06 [patent_title] => BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES [patent_app_type] => utility [patent_app_number] => 18/493623 [patent_app_country] => US [patent_app_date] => 2023-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42774 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18493623 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/493623
BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES Oct 23, 2023 Abandoned
Array ( [id] => 19778546 [patent_doc_number] => 12227570 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-18 [patent_title] => Anti-CEACAM6 antibodies and methods of use [patent_app_type] => utility [patent_app_number] => 18/383043 [patent_app_country] => US [patent_app_date] => 2023-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 52 [patent_no_of_words] => 10766 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18383043 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/383043
Anti-CEACAM6 antibodies and methods of use Oct 22, 2023 Issued
Array ( [id] => 18970387 [patent_doc_number] => 20240050479 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-15 [patent_title] => METHODS OF USING RARy AGONISTS FOR CANCER TREATMENT [patent_app_type] => utility [patent_app_number] => 18/481547 [patent_app_country] => US [patent_app_date] => 2023-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17284 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18481547 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/481547
Methods of using RARg agonists for cancer treatment Oct 4, 2023 Issued
Array ( [id] => 18923026 [patent_doc_number] => 20240026030 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => METHOD OF TREATING CANCER COMPRISING ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE [patent_app_type] => utility [patent_app_number] => 18/367446 [patent_app_country] => US [patent_app_date] => 2023-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47467 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 186 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18367446 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/367446
METHOD OF TREATING CANCER COMPRISING ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE Sep 11, 2023 Pending
Array ( [id] => 19067281 [patent_doc_number] => 20240101707 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => A METHOD OF PREVENTING, ALLEVIATING OR TREATING A TUMOR [patent_app_type] => utility [patent_app_number] => 18/454006 [patent_app_country] => US [patent_app_date] => 2023-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28741 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18454006 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/454006
A METHOD OF PREVENTING, ALLEVIATING OR TREATING A TUMOR Aug 21, 2023 Pending
Array ( [id] => 19263732 [patent_doc_number] => 20240207429 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 18/227830 [patent_app_country] => US [patent_app_date] => 2023-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 106007 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18227830 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/227830
LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME Jul 27, 2023 Pending
Array ( [id] => 19263721 [patent_doc_number] => 20240207418 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 18/227828 [patent_app_country] => US [patent_app_date] => 2023-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 105797 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 214 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18227828 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/227828
LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME Jul 27, 2023 Abandoned
Array ( [id] => 19050972 [patent_doc_number] => 20240092941 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => SINGLE-DOMAIN ANTIBODIES THAT BIND ROR1 [patent_app_type] => utility [patent_app_number] => 18/350617 [patent_app_country] => US [patent_app_date] => 2023-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25129 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18350617 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/350617
SINGLE-DOMAIN ANTIBODIES THAT BIND ROR1 Jul 10, 2023 Issued
Array ( [id] => 19684061 [patent_doc_number] => 20250002606 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-02 [patent_title] => Combination Therapy for Treating Cancer with an Antibody and Intravenous Administration of a Recombinant MVA [patent_app_type] => utility [patent_app_number] => 18/345511 [patent_app_country] => US [patent_app_date] => 2023-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34299 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18345511 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/345511
Combination Therapy for Treating Cancer with an Antibody and Intravenous Administration of a Recombinant MVA Jun 29, 2023 Pending
Array ( [id] => 19233780 [patent_doc_number] => 20240190972 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => Anti-Axl Antagonistic Antibodies [patent_app_type] => utility [patent_app_number] => 18/216085 [patent_app_country] => US [patent_app_date] => 2023-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35481 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18216085 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/216085
Anti-Axl Antagonistic Antibodies Jun 28, 2023 Abandoned
Array ( [id] => 18938232 [patent_doc_number] => 20240033371 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-01 [patent_title] => THERAPEUTIC COMBINATIONS COMPRISING ANTI-CD123 IMMUNOCONJUGATES [patent_app_type] => utility [patent_app_number] => 18/328288 [patent_app_country] => US [patent_app_date] => 2023-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36496 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18328288 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/328288
THERAPEUTIC COMBINATIONS COMPRISING ANTI-CD123 IMMUNOCONJUGATES Jun 1, 2023 Pending
Array ( [id] => 18707526 [patent_doc_number] => 20230330102 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => PROTAC ANTIBODY CONJUGATES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/310913 [patent_app_country] => US [patent_app_date] => 2023-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57879 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18310913 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/310913
PROTAC ANTIBODY CONJUGATES AND METHODS OF USE May 1, 2023 Pending
Array ( [id] => 19571920 [patent_doc_number] => 20240376212 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-14 [patent_title] => ALPHA V-INTEGRIN TARGETED SMALL MOLECULE DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 18/138935 [patent_app_country] => US [patent_app_date] => 2023-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20818 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18138935 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/138935
ALPHA V-INTEGRIN TARGETED SMALL MOLECULE DRUG CONJUGATES Apr 24, 2023 Pending
Array ( [id] => 18691066 [patent_doc_number] => 20230321267 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => Method And Molecules [patent_app_type] => utility [patent_app_number] => 18/191372 [patent_app_country] => US [patent_app_date] => 2023-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39820 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18191372 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/191372
Method And Molecules Mar 27, 2023 Abandoned
Menu